QULIPTA (nda215206)- (10MG,30MG,60MG)

Generic Name	ATOGEPANT	Innovator	ABBVIE
Dosage	10MG,30MG,60MG
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2035-Jan-30	NCE Excl Expiry	2026-Sep-28
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	4

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
10MG	**	**	Up	-	-
30MG	**	**	Up	-	-
60MG	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of QULIPTA